Patents Assigned to Biogen Idec
  • Biomarkers of Multiple Sclerosis
    Publication number: 20100284933
    Abstract: Biomarkers of multiple sclerosis (MS) and of anti-TWEAK/TWEAK-Receptor therapy for MS are described.
    Type: Application
    Filed: October 15, 2007
    Publication date: November 11, 2010
    Applicant: Biogen Idec MA Inc.
    Inventor: Linda C Burkly
  • Recombinant anti-VLA4 antibody molecules
    Patent number: 7829092
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: November 9, 2010
    Assignee: Biogen Idec MA Inc.
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • Antibodies to VLA-1
    Publication number: 20100272716
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Application
    Filed: March 19, 2010
    Publication date: October 28, 2010
    Applicant: Biogen Idec MA Inc.
    Inventors: Michael Karpusas, Paul D. Lyne, Jose William Saldanha, Ellen A. Garber
  • TREATMENT OF CANCER
    Publication number: 20100272721
    Abstract: Methods of treating cancer using an agent that blocks interaction between TWEAK and its receptor are described.
    Type: Application
    Filed: March 31, 2010
    Publication date: October 28, 2010
    Applicant: Biogen Idec MA Inc.
    Inventors: Linda C. Burkly, Jennifer Michaelson
  • Treatment of autoimmune diseases
    Patent number: 7820161
    Abstract: Methods are disclosed of treating rheumatoid arthritis in a human comprising administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab and administering methotrexate to the human.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: October 26, 2010
    Assignees: Biogen Idec, Inc., Genentech, Inc.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • Compositions and Methods to Treat Acute Myelogenous Leukemia
    Publication number: 20100266587
    Abstract: Compositions and methods for treating or preventing a hematologic malignancy, such as AML, using an anti-alpha4 antibody are described.
    Type: Application
    Filed: April 16, 2010
    Publication date: October 21, 2010
    Applicant: BIOGEN IDEC MA INC.
    Inventor: Karen McLachlan
  • RECEPTOR COUPLING AGENTS AND THERAPEUTIC USES THEREOF
    Publication number: 20100266542
    Abstract: Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed.
    Type: Application
    Filed: January 26, 2010
    Publication date: October 21, 2010
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Jeffrey L. BROWNING, Veronique BAILLY, Ellen GARBER
  • COMPOSITIONS AND METHODS FOR INCREASING VASCULARIZATION
    Publication number: 20100261654
    Abstract: Disclosed are methods of increasing vascularization in a tissue by administering a neublastin polypeptide to a mammal exhibiting impaired or inadequate blood flow in the tissue. The methods can be used to in the treatment or prevention of a disorder characterized by impaired or inadequate blood flow or to increase vascularization in an organ that has been transplanted into a subject.
    Type: Application
    Filed: May 1, 2008
    Publication date: October 14, 2010
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Biogen Idec MA Inc.
    Inventors: Anthony Rossomando, Jean-Sebastien Silvestre, Radia Tamarat
  • Modulators of Mitotic Kinases
    Publication number: 20100249067
    Abstract: The invention relates to compounds of Formula (I), a polymorph, an enantiomer, a stereoisomer, a solvate, an N-oxide derivative, or a pharmaceutically acceptable salt thereof: Formula (I), which have inhibitory effect on one or more protein kinases that are involved in cell mitosis.
    Type: Application
    Filed: January 30, 2008
    Publication date: September 30, 2010
    Applicant: Biogen Idec MA Inc.
    Inventors: Srinivas Rao Kasibhatla, Kevin Hong, Lin Zhang, Marcus F. Boehm, Junhua Fan, Jean-Yves LeBrazidec
  • Utilization of dialkylfumarates
    Patent number: 7803840
    Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: September 28, 2010
    Assignee: Biogen Idec International GmbH
    Inventors: Rajendra Kumar Joshi, Hans-Peter Strebel
  • Receptor coupling agents and compositions thereof
    Patent number: 7799902
    Abstract: Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: September 21, 2010
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Veronique Bailly, Ellen Garber
  • Carbocyclic and oxacarbocyclic fumaric acid oligomers
    Patent number: 7790916
    Abstract: The present invention relates to certain carbocyclic and oxacarbocyclic fumaric acid oligomers and the use thereof for preparing a pharmaceutical preparation as well of pharmaceutical preparations containing these compounds.
    Type: Grant
    Filed: April 3, 2003
    Date of Patent: September 7, 2010
    Assignee: Biogen Idec International GmbH
    Inventors: Rajendra Kumar Joshi, Hans-Peter Strebel
  • Nogo receptor binding protein
    Patent number: 7785829
    Abstract: The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.
    Type: Grant
    Filed: March 17, 2004
    Date of Patent: August 31, 2010
    Assignee: Biogen Idec MA, Inc.
    Inventors: Sha Mi, John McCoy, R. Blake Pepinsky, Daniel H. S. Lee
  • FC GAMMA RECEPTOR-BINDING POLYPEPTIDE VARIANTS AND METHODS RELATED THERETO
    Publication number: 20100203046
    Abstract: The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.
    Type: Application
    Filed: January 5, 2010
    Publication date: August 12, 2010
    Applicant: Biogen Idec MA Inc.
    Inventors: Herman van Vlijmen, Frederick R. Taylor, Ellen Garber
  • MODULATION OF TUMOR MICROENVIRONMENT
    Publication number: 20100203010
    Abstract: Compositions comprising CD80-targeted therapeutics and methods of using these compositions are provided for the treatment of a disease or disorder in which CD80-expressing cells or regulatory T cell function contribute to or exacerbate the associated pathology.
    Type: Application
    Filed: March 28, 2008
    Publication date: August 12, 2010
    Applicant: BIOGEN IDEC INC.
    Inventors: Kandasamy Hariharan, Shabnam Tangri, Arturo Molina
  • Cripto blocking antibodies and uses thereof
    Publication number: 20100202962
    Abstract: The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.
    Type: Application
    Filed: December 22, 2008
    Publication date: August 12, 2010
    Applicant: Biogen Idec Ma Inc.
    Inventors: Michele Sanicola-Nadel, Kevin P. Williams, Susan Gail Schiffer, Paul Rayhorn
  • NOGO Receptor Binding Protein
    Publication number: 20100204304
    Abstract: The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.
    Type: Application
    Filed: February 2, 2010
    Publication date: August 12, 2010
    Applicant: Biogen Idec MA Inc.
    Inventors: Sha Mi, John McCoy, R. Blake Pepinsky, Daniel H.S. Lee
  • RECOMBINANT ANTI-VLA4 ANTIBODY MOLECULES
    Publication number: 20100203042
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Application
    Filed: December 18, 2008
    Publication date: August 12, 2010
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
    Patent number: 7767687
    Abstract: The present invention provides compounds having the formula: wherein A-B together represent one of the following structures: n, R1, R2, R3, R4, L1, L2, Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., RAF), and thus are useful, for example, for the treatment of RAF mediated diseases.
    Type: Grant
    Filed: December 12, 2005
    Date of Patent: August 3, 2010
    Assignees: Biogen Idec MA Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Johan D. Oslob, Jiang Zhu, Kenneth Barr, Jennifer Cossrow, Brian Raimundo, Hiroko Tanaka
  • TREATMENT OF HODGKINS LYMPHOMA
    Publication number: 20100189716
    Abstract: Compositions comprising CD80 antagonists and methods using these compositions are provided for the treatment of Hodgkins lymphoma. More particularly, the disclosed CD80 antagonists may be used to induce apoptosis or lysis of Hodgkins Reed-Sternberg (HRS) cells, or to inhibit HRS cell activities that promote tumor development or progression.
    Type: Application
    Filed: March 28, 2008
    Publication date: July 29, 2010
    Applicant: BIOGEN IDEC INC.
    Inventors: Arturo Molina, Kandasamy Hariharan, Steffan Ho